Market Cap: $9.11B
PI
Protagonist Therapeutics, Inc.
PTGX
NASDAQ (NASDAQ Global Market)USD
Market Cap: $9.11B
Protagonist Therapeutics (Ticker: PTGX) is seeing a growing interest from institutional investors, indicating a strengthening position within the biopharmaceutical sector. Recent reports highlight tha…
Protagonist Therapeutics has positioned itself at the forefront of hematology research with its recent presentation of four abstracts focused on rusfertide, particularly concerning its applications in…
Groundbreaking Approval: Icotyde Launches New Era in Psoriasis Treatment In a pivotal advancement for psoriasis management, the U.S. Food and Drug Administration (FDA) grants approval to Johnson & Joh…
Protagonist Therapeutics Signals Strength Through Clinical Advancements in Q4 Report Protagonist Therapeutics (NASDAQ:PTGX) reveals a promising outlook in its recently announced Q4 earnings results, c…
Protagonist Therapeutics Advances Clinical Pipeline Amid Strategic Growth Initiatives Protagonist Therapeutics, a biopharmaceutical company, announces a significant advancement in its clinical pipelin…
Protagonist Therapeutics Advances Clinical Pipeline Amidst Strategic Growth Initiatives Protagonist Therapeutics releases its Q4 earnings results, revealing substantial progress in its clinical pipeli…
### Protagonist Therapeutics: Advancing Innovation in Targeted Therapies Protagonist Therapeutics is currently making strides in the development of novel therapies targeting unmet medical needs in gas…
Johnson & Johnson's Commitment to Innovation: A Key Driver of Growth Johnson & Johnson’s recent trajectory in 2023 underscores the importance of innovation in the healthcare sector. The company, which…
Protagonist Therapeutics and Johnson & Johnson: A Strategic Acquisition in Biopharmaceuticals Protagonist Therapeutics is currently the focus of acquisition discussions with Johnson & Johnson, a major…
Protagonist Therapeutics at the Forefront of Acquisition Talks with Johnson & Johnson Protagonist Therapeutics, a biopharmaceutical firm recognized for its innovative drug development, finds itself in…
Innovative Advances in Psoriasis Treatment: Protagonist Therapeutics and Johnson & Johnson's Collaborative Efforts Protagonist Therapeutics Inc. and Johnson & Johnson (JNJ) recently unveil new data fr…
Innovative Approaches in Psoriasis Treatment: Insights from the ICONIC-ADVANCE Studies Protagonist Therapeutics Inc. (PTGX) collaborates with Johnson & Johnson (JNJ) to advance the treatment landscape…
Innovative Developments in Psoriasis Treatment: Protagonist Therapeutics and Johnson & Johnson's Promising Findings Protagonist Therapeutics Inc. (PTGX) collaborates with Johnson & Johnson (JNJ) to ad…
Protagonist Therapeutics Strengthens Leadership with Appointment of Dr. Newman Yeilding Protagonist Therapeutics Inc. announces the appointment of Dr. Newman Yeilding as Executive Vice President and C…
Clear Street Expands Equity Research to Biotechnology Sector, Enhancing Client Offerings Clear Street, a cloud-native financial technology firm, announces an expansion of its equity research capabilit…
Clear Street Enhances Healthcare Focus with Biotechnology Research Expansion Clear Street, a cloud-native financial technology firm, takes a significant step in enhancing its equity research capabilit…